{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:18:25Z","timestamp":1794359905654,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Peptide Receptor Radionuclide Therapy (PRRT) delivers targeted radiation to Somatostatin Receptor (SSR) expressing Neuroendocrine Neoplasms (NEN). We sought to assess the predictive and prognostic implications of tumour dosimetry with respect to response by\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga DOTATATE (GaTate) PET\/CT molecular imaging tumour volume of SSR (MITV\n                      <jats:sub>SSR<\/jats:sub>\n                      ) change and RECIST 1.1, and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with gastro-entero-pancreatic (GEP) NEN who received LuTate followed by quantitative SPECT\/CT (Q-SPECT\/CT) the next day (Jul 2010 to Jan 2019) were retrospectively reviewed. Single time-point (STP) lesional dosimetry was performed for each cycle using population-based pharmacokinetic modelling. MITV\n                      <jats:sub>SSR<\/jats:sub>\n                      and RECIST 1.1 were measured at 3-months post PRRT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median of 4 PRRT cycles were administered to 90 patients (range 2\u20135 cycles; mean 27.4\u00a0GBq cumulative activity; mean 7.6\u00a0GBq per cycle). 68% received at least one cycle with radiosensitising chemotherapy (RSC). RECIST 1.1 partial response was 24%, with 70% stable and 7% progressive disease. Cycle 1 radiation dose in measurable lesions was associated with local response (odds ratio 1.5 per 50\u00a0Gy [95% CI: 1.1\u20132.0],\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.002) when adjusted by tumour grade and RSC. Median change in MITV\n                      <jats:sub>SSR<\/jats:sub>\n                      was -63% (interquartile range -84 to -29), with no correlation with radiation dose to the most avid lesion on univariable or multivariant analyses (5.6 per 10\u00a0Gy [95% CI: -1.6, 12.8],\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.133). OS at 5-years was 68% (95% CI: 56\u201378%). Neither baseline MITV\n                      <jats:sub>SSR<\/jats:sub>\n                      (hazard ratio 1.1 [95% CI: 1.0, 1.2],\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.128) nor change in baseline MITV\n                      <jats:sub>SSR<\/jats:sub>\n                      (hazard ratio 1.0 [95% CI: 1.0, 1.1],\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.223) were associated with OS when adjusted by tumour grade and RSC but RSC was (95% CI: 0.2, 0.8,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.012).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Radiation dose to tumour during PRRT was predictive of radiologic response but not survival. Survival outcomes may relate to other biological factors. There was no evidence that MITV\n                      <jats:sub>SSR<\/jats:sub>\n                      change was associated with OS, but a larger study is needed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06257-6","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T10:25:02Z","timestamp":1684146302000},"page":"2997-3010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1248-0967","authenticated-orcid":false,"given":"R.","family":"Alipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"6257_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","volume":"733","author":"EP Krenning","year":"1994","unstructured":"Krenning EP, Kooij PP, Bakker WH. Radiotherapy with a radiolabeled somatostatin analogue, -octreotide. A case history. Ann New York Acad Sci. 1994;733:496\u2013506.","journal-title":"Ann New York Acad Sci"},{"key":"6257_CR2","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","volume":"10","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, De Jong M, Kooij PP. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10:S23-29.","journal-title":"Ann Oncol"},{"key":"6257_CR3","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124\u201330 American Society of Clinical Oncology (ASCO).","journal-title":"J Clin Oncol"},{"key":"6257_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR5","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00259-014-2788-5","volume":"41","author":"G Kong","year":"2014","unstructured":"Kong G, Thompson M, Collins M, Herschtal A, Hofman MS, Johnston V, et al. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging. 2014;41:1831\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR6","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol Am Soc Clin Oncol (ASCO). 2008;26:3063\u201372.","journal-title":"J Clin Oncol Am Soc Clin Oncol (ASCO)"},{"key":"6257_CR7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-017-1273-x","volume":"58","author":"E Leoncini","year":"2017","unstructured":"Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017;58:368\u201379 Springer Science and Business Media LLC.","journal-title":"Endocrine"},{"key":"6257_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"6257_CR9","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2021.39.15_suppl.4112","volume":"39","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar AE, et al. Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J Clin Oncol. 2021;39:4112\u20134112 American Society of Clinical Oncology (ASCO).","journal-title":"J Clin Oncol"},{"key":"6257_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","volume":"41","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925\u201333 Springer Science and Business Media LLC.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105:295\u2013309.","journal-title":"Neuroendocrinology"},{"key":"6257_CR12","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","volume":"45","author":"U Garske-Rom\u00e1n","year":"2018","unstructured":"Garske-Rom\u00e1n U, Sandstr\u00f6m M, Fr\u00f6ss Baron K, Lundin L, Hellman P, Welin S, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45:970\u201388 (Springer Nature).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR13","doi-asserted-by":"publisher","unstructured":"Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Luoctreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728-742. https:\/\/doi.org\/10.1007\/s00259-018-4209-7","DOI":"10.1007\/s00259-018-4209-7"},{"key":"6257_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.114.148437","volume":"56","author":"E Ilan","year":"2015","unstructured":"Ilan E, Sandstr\u00f6m M, Wassberg C, Sundin A, Garske-Rom\u00e1n U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177\u201382 Society of Nuclear Medicine.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"6257_CR15","first-page":"92S","volume":"46","author":"S Pauwels","year":"2005","unstructured":"Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):92S-S98.","journal-title":"J Nucl Med"},{"key":"6257_CR16","doi-asserted-by":"publisher","first-page":"112503","DOI":"10.1118\/1.4824318","volume":"40","author":"PA Jackson","year":"2013","unstructured":"Jackson PA, Beauregard J-M, Hofman MS, Kron T, Hogg A, Hicks RJ. An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT\/CT imaging. Med Phys. 2013;40:112503 Wiley.","journal-title":"Med Phys"},{"key":"6257_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1102\/1470-7330.2011.0012","volume":"11","author":"J-M Beauregard","year":"2011","unstructured":"Beauregard J-M, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT\/CT system. Cancer Imaging. 2011;11:56\u201366 (E-MED LTD).","journal-title":"Cancer Imaging"},{"key":"6257_CR18","doi-asserted-by":"publisher","unstructured":"Gustafsson J, Taprogge J. Theoretical aspects on the use of single-time-point dosimetry for radionuclide therapy. Phys Med Biol [Internet]. 2022;67. Available from: https:\/\/doi.org\/10.1088\/1361-6560\/ac46e0","DOI":"10.1088\/1361-6560\/ac46e0"},{"key":"6257_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5\u201319 (Springer Science and Business Media LLC).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR20","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BLR, Teunissen JJM, Kooij PP, et al. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43:1802\u201311 (Springer Nature).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR21","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","volume":"46","author":"I Goncalves","year":"2019","unstructured":"Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, et al. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Eur J Nucl Med Mol Imaging. 2019;46:1902\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer."},{"key":"6257_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00259-013-2504-x","volume":"40","author":"R Kashyap","year":"2013","unstructured":"Kashyap R, Jackson P, Hofman MS, Eu P, Beauregard J-M, Zannino D, et al. Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. Eur J Nucl Med Mol Imaging. 2013;40:1853\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.113.125336","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Gr\u00fcnwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55:183\u201390.","journal-title":"J Nucl Med"},{"key":"6257_CR25","first-page":"1632","volume":"34","author":"A Bockisch","year":"1993","unstructured":"Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med. 1993;34:1632\u20138.","journal-title":"J Nucl Med"},{"key":"6257_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H\u00e4nscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a Single Measurement After 4 Days. J Nucl Med. 2018;59:75\u201381.","journal-title":"J Nucl Med"},{"key":"6257_CR27","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/mp.12886","volume":"45","author":"MT Madsen","year":"2018","unstructured":"Madsen MT, Menda Y, O\u2019Dorisio TM, O\u2019Dorisio MS. Technical Note: Single time point dose estimate for exponential clearance. Med Phys. 2018;45:2318\u201324 (Wiley).","journal-title":"Med Phys"},{"key":"6257_CR28","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","volume":"61","author":"PA Jackson","year":"2020","unstructured":"Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT\/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. J Nucl Med. 2020;61:1030\u20136.","journal-title":"J Nucl Med"},{"key":"6257_CR29","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.2967\/jnumed.120.256255","volume":"62","author":"TP Devasia","year":"2021","unstructured":"Devasia TP, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT\/CT After 177Lu-DOTATATE. J Nucl Med. 2021;62:1118\u201325.","journal-title":"J Nucl Med"},{"key":"6257_CR30","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/cancers13050962","volume":"13","author":"U Jahn","year":"2021","unstructured":"Jahn U, Ilan E, Sandstr\u00f6m M, Lubberink M, Garske-Rom\u00e1n U, Sundin A. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE; Differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms. Cancers (Basel). 2021;13:962 (MDPI AG).","journal-title":"Cancers (Basel)"},{"key":"6257_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2967\/jnumed.118.217745","volume":"60","author":"RJ Hicks","year":"2019","unstructured":"Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, et al. 64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. J Nucl Med. 2019;60:777\u201385.","journal-title":"J Nucl Med"},{"key":"6257_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s00259-018-4196-8","volume":"46","author":"G Kong","year":"2019","unstructured":"Kong G, Grozinsky-Glasberg S, Hofman MS, Akhurst T, Meirovitz A, Maimon O, et al. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Eur J Nucl Med Mol Imaging. 2019;46:718\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6257_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-15-0119","volume":"22","author":"M Heetfeld","year":"2015","unstructured":"Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22:657\u201364.","journal-title":"Endocr Relat Cancer"},{"key":"6257_CR34","first-page":"12S","volume":"62","author":"G Sgouros","year":"2021","unstructured":"Sgouros G, Dewaraja YK, Escorcia F, Graves SA, Hope TA, Iravani A, et al. Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. J Nucl Med. 2021;62:12S-22S.","journal-title":"J Nucl Med"},{"key":"6257_CR35","doi-asserted-by":"publisher","first-page":"10196","DOI":"10.1038\/s41598-020-67199-9","volume":"10","author":"C Cullinane","year":"2020","unstructured":"Cullinane C, Waldeck K, Kirby L, Rogers BE, Eu P, Tothill RW, et al. Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci Rep. 2020;10:10196.","journal-title":"Sci Rep"},{"key":"6257_CR36","unstructured":"PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours - Full Text View - Clinicaltrials.gov [Internet]. Available from: \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT05053854. Accessed\u00a021 Aug 22"},{"key":"6257_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.117.189712","volume":"59","author":"H Bergsma","year":"2018","unstructured":"Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLBLR, Teunissen JJM, et al. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2018;59:452\u20138.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06257-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06257-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06257-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T22:04:58Z","timestamp":1690581898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06257-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6257"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06257-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"3 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No: retrospective analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Human Research Ethics Committee (HREC) waiver obtained for the requirement of consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Rodney J Hicks is a shareholder in Telix Pharmaceuticals and on the Scientific Advisory Board of Revela. He is the founder and part-owner of PreMIT Pty Ltd and Precision Molecular Imaging and Theranostics Pty Ltd. Other authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}